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Backgrounds: High-speed Video-Microscopy Analysis (HVMA) is now being used to aid diagnosis of Primary Ciliary
Dyskinesia (PCD). Only a few centers however, are equipped with the available resources and equipment to perform
these tests. We describe our experience in HVMA reaching-out to many more peripheral and relatively remote
areas.
A portable computer with HVMA software, video camera and a microscope were used. Fourteen disperse pediatric
centers were reached and a total of 203 subjects were tested within a relatively short time (Clinical Trial
Registration: NCT 01070914 (registered February 6, 2010).
Results: With an average time of 20 minutes per patient, the system enabled us to test approximately 10–15
subjects per day. A valid HVMA result was made in 148 subjects and helped in the diagnosis of PCD in many of the
patients who were subsequently confirmed to have PCD by electron microscopy and/or immunofluoresence and/
or genetics and/or nasal Nitric Oxide testing. The sensitivity of abnormal HVMA to accurately predict PCD was
90.2%.
Discussion and conclusion: This is the first report of an out-reach system to record HVMA for improved diagnosis
of PCD in remote regions that are not within reach of PCD centers and experts. It provides immediate preliminary
results and instantaneous feedback to the physician, patient and his/her family members in these areas. Future
studies to compare this system to conventional desk top systems are warranted.
Trial registration: NCT 01070914 (registered February 6, 2010).
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Primary ciliary dyskinesia (PCD) is an inherited disorder
characterized by recurrent infections of the upper and
lower respiratory tract, reduced fertility in males and situs
inversus in about 50% of affected individuals [1,2].
Respiratory ciliary motility dysfunction is a major feature
of PCD and has been traditionally evaluated by simple
light microscopy of ciliated epithelium cells. Although this
approach may identify markedly diminished or absent beat
frequency, ciliary beating may appear normal in some
cases of PCD [1,3]. Moreover, it has become apparent that
assessment of both ciliary beat pattern and frequency are* Correspondence: amirav@012.net.il
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unless otherwise stated.essential as cilia may beat in a dyskinetic fashion while
maintaining their normal beat frequency [4,5]. Therefore,
the use of conventional light microscopic assessment of
ciliary motility is no longer recommended as a screening
technique. With recent advances in High-speed imaging,
High-speed Video-Microscopy analysis (HVMA) evaluat-
ing both ciliary beat pattern and frequency is now used as
part of routine diagnostic testing of PCD [1,4,5]. With this
method a camera is attached to a microscope and the
brushing specimen are placed under the microscope, after
which images are recorded and analyzed. Only a handful
of laboratories are equipped with the available resources
and specialized equipment to perform these tests. Highly
centralized centers equipped with HVMA technologies
have been developed [6] where patients are referred for
diagnostic purposes.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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has been suggested that samples taken at the patient’s local
point of care be transported to the diagnostic center. This
also has many drawbacks such as sample degradation due
to transport delays as well as problems with standardization
of procedures.
The aim of this paper is to describe our experience
implementing a reach out system in order to enhance
and complement diagnostic work-up for PCD in remote
areas usually lacking access to sophisticated diagnostic
settings.
Methods
A study to characterize all known and suspected PCD pa-
tients in Israel (NCT 01070914) is currently being under-
taken in Israeli pediatric pulmonology centers using
multiple diagnostic PCD tests. The study is in compliance
with the Helsinki Declaration and ethical approval was ob-
tained from the local research committee at each centre
that collected patients’ data (Ziv Medical Center, Schneider
Children’s Medical Center, Edith Wolfson Medical Center,
Soroka Medical Center, Hadassah-Hebrew University
Medical Centers, Rambam Medical Center, Western
Galilee Hospital, Saint Vincent De-Paul Hospital, Assaf
Harofeh Medical Center, Shaare Zedek Medical Center,
Edmond & Lili Safra Children’s Hospital, Sheba Medical
Center, Carmel Medical Center, Dana Children’s Hospital)
as well as from the Israeli Ministry of Health. Informed
consent was obtained from each subject or his/her guard-
ian. Inclusion criteria were 1. Diagnosis of PCD (mostly
clinical diagnosis and sometimes other partial ancillary test
results, mainly electron microscopy) or 2. Suspected PCD
based on unexplained Situs Inverses, chronic pulmonary or
ENT symptoms and/or signs, fertility disorders or family
members with suggestive clinical history of PCD.
Following recruitment each subject completed an in depth
clinical history, before undergoing nasal brushing [for
Electron Microscopy (EM), Immuno-fluorescence (IF) and
video-microscopy], blood sampling (for genetic analysis) and
measurement of nasal Nitric Oxide (NO). Thus, each sub-
ject underwent all of these 5 tests including an HVMA
evaluation of his/her cilia. The nasal brushing material
was first used for HVMA and the remaining was used for
IF staining and EM. NO measurements were obtained ac-
cording to established American Thoracic Society guide-
lines. A single manufacture unit (CLD 88 SP, Eco Physics
Duernten, Switzerland) was used in all centers. Most of
the NO tests were done by a single team of investigators
(MP, DB) with the same unit. Some of the NO tests were
done by the experienced technicians at local centers using
identical standardized operating procedures (Single breath
with breath hold). The average of three measurements
was used for statistical analysis. In young children (usually
less than 4 years) the tidal breath method was employed.The analyzers were calibrated according to the manufac-
turer’s specifications.
The procedure for HVMA started by obtaining respira-
tory epithelial cells from the patient by nasal brushing using
a conventional cervix cytology brush [Celletta™ brush cell
collector with protective tip (product number 9100060;
Engelbrecht Medizin-und Labortechnik GmbH,
Tiefenbachweg 13; 34295 Edermünde, Germany)]. The first
author has been trained in nasal brushing by experienced
investigators (HO, CW, MS) before the present study. To
minimize pain, the brush was rinsed with an isotonic sa-
line solution before being inserted in the inferior nasal
meatus, using rotatory and linear movements. The brush
was immediately removed and transferred into a tube con-
taining 2–3 mL of cell culture medium (RPMI Medium
1640, Endotoxin tested, Cell culture tested, without
L-Glutamine, without Sodium Bicarbonate. Biological
Industries LTD., Beit Haemek, Israel). The tube was then
shaken vigorously so that cells became detached from the
brush. The brush was withdrawn from the tube and used
to smear slides (for later IF analysis) while the last portion
of the material on the brush was stored in a glutaraldehyde
filled tube for later EM analysis.
A plastic Pasteur pipette was then used to draw approxi-
mately 50 microliter fluid sample from the RPMI tube and
put it in one of the wells of a multi-well cassette under the
microscope. Traditional HVMA uses single slides per sam-
ple and each fluid sample is put on a new slide for the
HVMA. In this case we used a Linbro multiwell plate
(Figure 1, Hampton Research Corp., CA, USA). This is a 24
well plate where the wells were identified by lettered rows A
through D and numbered columns 1 through 6. It allowed
multiple fluid samples to be placed in the wells with no need
to remove the plate from the microscope holder between
patients. The use of the multi-well plate instead of individ-
ual glass slides minimized microscope movements (during
slides changes) and the need for focus adjustments.
All sample images were visualized with a relatively
small Eclipse TS-100 inverted phase contrast microscope
(Nikon Corp. Tokyo, Japan) using a 40X objective lens
(numerical apparatus = 0.55) providing a total magnifica-
tion of 400 X. Eight to ten video images of each sample
under the microscope were selected for recording based
upon the visibility of vital ciliated cells, good resolution
and preferably, the presence of cell strips. Images were
recorded using a scA640-120 fm digital video camera
(Basler AG, Ahrensburg, Germany) attached to the micro-
scope. The camera was connected to a laptop computer
(LG model #R58) with an IEEE cable. The computer was
equipped with a high power video card and an Express
card IEEE1394B interface (Figure 2). The laptop computer
was easily transportable and the whole system was packed
on a heavy duty trolley (Pelican 1630, Pelican Products,
Inc., CA, USA) for transport.
Figure 1 Use of a 24 well plate for microscopy.
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with the Sisson-Ammons Video Analysis (SAVA) system
[7], which was highly customized to perform ciliary analysis
for both ciliary beating frequency (CBF) and patterns.
Images were captured initially into RAM in real-time at
120 fps and immediately compressed and stored to disk.
At a sampling rate of 120 fps, approximately 3 s of video
were recorded for each image. Each digital image frame
consisted of 640 columns X 480 rows of pixels.
Images were recorded at room temperature within
10 minutes after brushing. Once recorded, the video clipsFigure 2 Components of the HVMA system.for each subject (and sample) were played back in normal
time and slow motion (up to 1/8th speed) for quality as-
sessment and analysis of beat frequency and pattern. If the
quality was deemed inadequate, we used the pipetor to
draw a second sample from the tube into another well. If
this was also insufficient, a second nasal brushing was per-
formed on the subject and the process was repeated.
Once this process was deemed satisfactory, the subject
had completed his test and the system was immediately
ready for the next subject. An initial preliminary assess-
ment of the video clips was done on-site and a general
subjective impression (general 3 categories of normal or
likely normal; abnormal or possibly abnormal; and un-
determined) was immediately shared with the treating
physicians (and also with the patient and his/her family)
who were usually present at the site but may not always
attend similar tests done in centralized institutions. With
a few simple clicks in the SAVA software, the next sub-
ject’s details appeared on the screen and the system was
ready for the next subject’s sample.
A much more thorough and comprehensive detailed ana-
lysis of the video clips was performed post hoc at the cen-
tral laboratory where each video clip was played back and
analyzed separately and a final result of findings was pre-
pared. This analysis and interpretation was done by 3 ex-
perts in HVMA who were not involved in the data
collection (2 from Germany, 1 from the UK) and were
blind to the clinical data, NO EM, IF or genetic results of
the subject. In cases of ambiguity the files were further re-
analyzed and final report was reached by consensus.
Analysis of each video clip included quality of image (im-
ages with no epithelia cells and/or clips with only single
cells were excluded from further analysis), and beating pat-
tern. Reviewing all 8–10 images for each subject and taking
into account all of these criteria, the HVMA results of each
subject were then categorized into the following specific
categories [8]: Normal or Probably Normal beating (regular
forward and recovery strokes); Immotile cilia; Residual
Table 1 Results of post –hoc and on-site HVMA in all
study subjects (n = 203) and in PCD patients (n = 112)
(CBA = cannot be assessed)
Post Hoc On-Site
Category All PCD All PCD
Immotile 45 39 47 41
Residual 15 14 15 14
Stiff 36 18 37 18
Circular 6 2 6 2
Hyperkinetic 2 1 2 1
Normal 44 8 44 8
CBA 49 28 46 26
No video 6 2 6 2
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ments); Stiff beating (due to reduced bending capacity/
amplitude); Abnormal circular beating; Hyperkinetic cilia;
No video available; Cannot be assessed. The last category
(cannot be assessed) included subjects with poor quality
clips for different causes such as those with single (not
within an epithelial strip) immotile ciliated cells, poor
resolution due to cells entrapped in mucus or subjective
inability to distinguish between cilia of dying or damaged
cells (secondary dyskinesia) to dyskinesia or a-kinetic cilia
in a vital cell (primary dyskinesia). In these cases, nasal
brushing and HVMA should be repeated three to six
months later.
The diagnosis of PCD was confirmed following the
completion of the study and based on assessment of all
available tests for each individual. In addition to pre-
determined classic clinical characteristic as an inclusion
criteria, confirming the diagnosis of PCD in this study
required at least 2 abnormal tests out of the 5 tests per-
formed (EM, IF, Genetics, NO and HVMA). The distri-
bution of various HVMA findings in the PCD diagnosed
patients were then summarized post-hoc.
The sensitivity of HVMA as an index test to accurately
diagnose PCD was calculated as the proportion of abnor-
mal HVMA in the total number of confirmed PCD. For
the purpose of sensitivity calculation, PCD was confirmed
by the presence of at least two abnormal references tests
out of four (EM, IF, Genetics, NO; without the index test-
HVMA)]. As there is no gold standard for PCD [9] it is
very challenging to exclude PCD and to calculate specificity
and/or negative predictive value of diagnostic tests. For ex-
ample, even when PCD is defined by abnormal genetics, it
is impossible to define “non PCD” (true negative, false posi-
tive) cases, as a subject who is negative for known PCD
mutations can still harbor a new unrecognized PCD caus-
ing mutation. Therefore, we have focused on calculating
the sensitivity of HVMA, namely the probability of an ab-
normal HVMA in subjects with PCD.
Findings and results
Using this mobile system we have so far performed
HVMA tests in 203 subjects in 14 different pediatric pul-
monology centers throughout the country. With an ap-
proximate 20 minutes testing time per patient, from
brushing to complete analysis of the ciliary beating pat-
tern, we were able test 10–15 subjects per day. Apart from
individual transport time to each center location, it took
another hour to reassemble and disassemble the system in
each location.
Failure to obtain epithelial cells was infrequently ob-
served on initial testing and gradually disappeared later on.
Although not formally assessed, we have noticed decreased
variability and increased expertise in both brushing and
video analysis over time. Altogether, approximately 1500video clips were analyzed. Six subjects had no adequate
samples and/or no video recording. In another 49 subjects,
a HVMA result was determined to be “cannot be assessed”.
An HVMA result was made in 148 out of 203 (73%) sub-
jects. The results of HVMA are depicted in Table 1,
Figure 3 (on site results in all subjects) and Figure 4 (post
hoc results in PCD patients). Although the HVMA cat-
egories were different between the initial on-site assess-
ment (3 general categories) and the post-hoc assessment (7
specific categories), there was a high degree of agreement
between the two, with only 6 subjects whose final post-
hoc results were not within the initial on-site general
categories.
PCD was confirmed in 112 subjects. Detailed results
of HVMA of these 112 PCD patients (which were diag-
nosed in our study according to the previous definition),
are depicted in Table 1 and Figure 4.
The sensitivity of on-site abnormal HVMA (index test)
to accurately predict PCD (defined as at least 2 abnor-
mal reference tests out of 4) was 90.5%. It was not differ-
ent from the post-hoc HVMA sensitivity (90.2%).
Although no diagnosis of PCD was made on-site, invit-
ing the parents, primary physician and/or the patient to
view the video on-site within minutes after the brushing
was highly appreciated and rewarding for many of them.
Discussion
This is the first report of an out-reach system to record
HVMA of cilia for improving diagnosis of PCD. The port-
able system was used successfully in the evaluation of pa-
tients in regions that are not within easy reach of PCD
centers and experts. Currently in Israel, there is only one
center equipped with a stationary HVMA and many pa-
tients, as well as physicians, are reluctant to bear the travel
expense and long time constraints involved. According to
a recent study in 290 centers treating PCD throughout
Europe [10], only 27% reported being able to perform
HVMA varying from 52% in the British Isles to only 7% in
Figure 3 HVMA on-site results (percentage of each category) in
all subjects (n = 203) (CBA = cannot be assessed).
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confined to specialized centers, [11] the present method
allows for better access to remote places and allows pa-
tients to be tested close to or even in their hometown
without the need for long distance travel.
The results of the present study demonstrate that
HVMA using a reach-out system can be used as a comple-
mentary test to aid in the diagnosis of PCD. Sensitivity of
the reach-out HVMA system to predict PCD in this study
was 90%. It was no different from the sensitivity calculated
using off-site HVMA. It is interesting to note the sensitivity
measured in the present study was similar to the sensitivity
of HVMA (defined as “dyskinesia score equal or exceeding
2”) to predict PCD reported by Stannard et al. [4].Figure 4 HVMA post-hoc results (percentage of each category)
in PCD patients (n = 112).It must be acknowledged that we have used only a single
brushing which may have over-estimated the true abnor-
mal cases of PCD due to potential inclusion of secondary
motion abnormalities. Thus, the current calculated sensi-
tivity of the test may be under-estimated. For clinical pur-
poses however, the inclusion of other tests in these cases
reduced this potential drawback.
Portability and access to diagnostic tests is of great im-
portance particularly with rare diseases. It has been known
that PCD is underdiagnosed [2,12]. The effects of under-
diagnosis may have a stronger impact in remote areas
where inhabitants have little chance of being diagnosed and
treated properly without leaving their jobs and travelling
long distances, sometimes taking days to reach the closest
PCD referral center. Wrong diagnosis in patients with
bronchiectasis can be harmful, because other disorders (e.g.
Common variable immunodeficiency syndromes) are
treated differently than PCD, and timely diagnosis and early
treatment may produce a decrease in morbidity [13].
PCD care requires a reasonable compromise between
centralized treatment by highly specialized expert teams
at large time intervals and frequent visits at small local
centers with limited expertise. Our portable HVMA of-
fers complementary state-of-the-art PCD diagnostics to
patients and, at the same time, provides specialized
knowledge to physicians at smaller centers. This is ideal
for regions with few, scattered experienced centers and
reluctance of patients to travel long distances to undergo
diagnostic testing. However, in societies, where travelling
is not an important obstacle, a portable HVMA system
will not be of additional value.
Due to the identical analysis methodology used in a sta-
tionary system, the current portable HVMA system, al-
though smaller and much less expensive than fixed
systems, should not lack in relative quality or functional-
ity. The ease of use is also a big advantage. Thus, the
technological aspects of the system may, in the future,
allow rural sites to achieve tertiary site image quality with
basic training. From our experience it can be estimated
that 50 nasal brushings should be practiced to acquire
good hands on expertise. A dedicated physician, techni-
cian or nurse with appropriate training and could be the
core of future similar reach out teams. Gaining of expert-
ise by the team in performing the tests will further
strengthen the system.
Of course there is a value in centralized care and diagno-
sis, yet our current approach also takes the patients’ needs
and satisfaction into account. Although we have no data to
compare, it is a reasonable assumption that patients’ rate of
compliance with testing may be higher compared to their
compliance when using a long distance center.
The use of a single plastic plate containing multiple
wells allows us to save a lot of time. There is no need to
open the microscope slide holders at all, the plastic plate
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hospital, and it is also more economical.
The video acquiring system could be operated by one
or two technicians travelling from site to site. Data could
be sent on-line back to a doctor or a central laboratory
if further analysis is necessary.
In this specific study, in addition to HVMA on-site
testing, the NO measurements were also performed on-
site using a single manufacture large unit (CLD88). In
the future, with the advance in portable NO analyzers,
reach-out systems may also include portable NO ana-
lyzers, further strengthening the diagnostic yield of a
reach-out system.
Some limitations need to be acknowledged: when the
number of subjects per center is small, travelling to a re-
mote area may be economically inefficient. However, a for-
mal economic comparison with office based testing was
beyond the scope of our study. As PCD is a rare disease, it
is likely that the number of subjects requiring PCD diag-
nostic testing will decrease after most previously undiag-
nosed individuals have been identified. This is a welcome
effect accompanying any introduction of standardized care
in rare diseases. Another technical limitation of our study
is that temperature is not controlled in the approach de-
scribed. That means that, in general, the temperature is
around 24°C due to the heat generated by the microscope.
Some researchers believe it is important to perform
HVMA at 37°C [14]. We do not consider it a major draw-
back as, in our experience, as well as that of others [15],
ciliary beat patterns do not significantly vary at different
temperatures. Furthermore, lower temperature reduces
beat frequency which in turn allows better visualization
and capturing of very fast beat variants. [8] The “lower”
(x400) magnification in our portable system may reduce
resolution compared to other systems. However, as shown
recently by our group, higher magnification markedly re-
duced depth of focus in the Z plane and limits ciliary mo-
tion interpretation (see video s20 in Ref. [8]). The
magnification used in the present portable system is iden-
tical to the stationary one used routinely in our Germany
center [8]. Standardization of HVMA is crucial in both
stationary and reach-out system and this will require more
discussion and consensus [9].Conclusions
We have described our successful experience with a new
reach-out HVMA system for PCD diagnosis. The system
may improve quality of care by enabling large scale test-
ing to be efficiently done in any remote or non-remote
center, enabling HVMA to be accessible to a greater
number of patients suspected of suffering from PCD.
Future studies to compare this system to conventional
desk top systems are warranted.Abbreviations
HVMA: High speed video microscopy analysis; PCD: Primary ciliary dyskinesia;
CBF: Ciliary beat frequency.
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